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Background: Bisphosphonates have been widely used for treatment of high bone resorption states. It lowers bone
turnover by inhibiting osteoclasts bone resorption with various mechanisms of actions: inhibition of osteoclast
formation and attachment to the bone surface, induction of metabolic injury, alteration of vesicle trafficking and
induction of osteoclast apoptosis. Bone biopsies studies from patients under bisphosphonates have shown that
some resorption parameters are decreased as expected but the number of osteoclasts seems not to be necessarily
decreased. The description of osteoclasts morphology from patients treated with bisphosphonates has rarely been
reported in the literature.
Case presentation: We describe in this paper two patients treated with bisphosphonates from whom iliac crest
bone biopsies have shown large, multinucleated and apoptotic osteoclasts that were not associated with bone
resorption activities. The characteristics of these osteoclasts are described and the literature reviewed.
Conclusion: The appropriate recognition of these giant osteoclasts in bone tissues from patients treated with
bisphosphonates is of primary importance for bone pathologists and should not be interpreted as signs of
increased bone resorption as seen in hyperparathyroidism, bone cancer or Paget’s disease of bone.
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Bisphosphonates (Bps) constitute a major class of drugs
used to treat various metabolic bone diseases including
osteoporosis, metastatic or post-transplant bone disease.
Since their introduction more than thirty years ago,
many studies have shown that they mainly act through
inhibition of osteoclasts (OC) bone resorption: inhibition
of OC formation [1] or attachment to the bone surface
[2], induction of metabolic injury to OC [3], alteration of
vesicle trafficking and/or induction of OC apoptosis [4].
The anti-osteoclastic effects of nitrogen-containing Bps
(including alendronate (ALN) and risedronate (RIS)) re-
sult from inhibition of the enzyme farnesyl pyrophosphate
synthase that ultimately leads to OC death [5]. The de-
crease in circulating markers of bone resorption in Bps-
treated patients has been extensively documented, using* Correspondence: fabrice.mac-way@mail.chuq.qc.ca
1Laboratoire de Biologie Intégrative du Tissu Osseux, Inserm U1059,
Université de Lyon, Saint-Etienne, France
2Division of Nephrology, CHU de Québec, L’Hôtel-Dieu de Québec Hospital
and Research Center, Faculty of Medicine, Laval University, Quebec, Canada
Full list of author information is available at the end of the article
© 2014 Mac-Way et al.; licensee BioMed Centr
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.measurements of collagen breakdown products in urine
or serum [6] and has been used to monitor patients com-
pliance or predict Bps efficacy [7]. While bone histomor-
phometry studies mentioned the reduction of resorption
rate [8], period [9] or lacunae depth [10] in patients
treated with Bps, the number of OC has been reported to
be lowered, normal or even increased. In fact, the descrip-
tion of their morphology has rarely been reported in the
literature. In this paper, we report two cases in which bone
biopsies from patients under Bps showed unusual giant,
multinucleated OC that were not associated with resorp-




A 41 year-old woman known for a relapsing Cushing
syndrome with two previous unsuccessful pituitary sur-
geries and multiple fractures history underwent an iliac
crest bone biopsy while under oral Bps for three years.
Six and four years before, she suffered respectively from
bilateral metatarsal fractures and a spontaneous rightal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Evolution of biological parameters and BMD in patient 1
-48 months -24 months -12 months Bone biopsy -6 months -12 months -36 months
Deoxypyridinoline
(8.2-20.2 nmol/mmol creat)
16.8 4.3 8.3 8.9 24.1 14.6 6.9
Intact PTH (10-65 pg/mL) 27.4 ND ND 37.3 ND 52.1 65.1
25-(OH) D (20-90 nmol/L) 45 ND ND 57 ND 79 94
Alkaline phosphatase (30-125 U/L) 72 ND ND 53 97 93 47
BMD (T-score)
Lumbar -1.2 -1.3 ND -1.1 -1.2 -0.8 ND
Femoral neck -0.6 -0.7 -0.4 -0.2 -0.6
PTH: Parathyroid hormone; BMD: Bone mineral density; ND: not determined.
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cium (500 mg twice daily), vitamin D (400 i.u twice
daily) and ALN (70 mg/week) were started (see Table 1
for period under treatment). Subsequently, she suffered
from two other episodes of fractures: left ischium and
left femoral neck fractures. Each of her hospitalisations
included biochemistry tests that were normal except for
an elevated blood cortisol (>744 nmol/l, normal range:
120-620 nmol/l) and osteopenia (Table 1) so she finally
underwent a successful total hypophysectomy in the year
preceding the bone biopsy. Because she continued to
fracture while under Bps, she was switched from ALN to
teriparatide (TPTD) soon after her bone biopsy. Bone
mineral density (BMD) measurement 6 months and two
years after TPTD introduction showed normal T-score
values but unfortunately she continued to experience
fractures while under TPTD: left foot (two times) and
right ischium. After 18 months of TPTD treatment, she
was put back on Bps (RIS 35 mg/week) for the following
two years. Still, she suffered from right metatarsal and
left cuneiform fractures so RIS was furtherly changed for
ranelate strontium. The histomorphometric parameters
are reported in Table 2. The Bone Formation Rate (BFR)Table 2 Histomorphometric parameters for patient 1
and 2
Parameters Patient 1 Patient 2 Normal range
BV/TV (%) 37.3 22.3 21.9 ± 3.3
OV/BV (%) 0.6 0.6 2.0 ± 1.2
MAR (μm/j) 0.92 0.53 0.72 ± 0.12
MS/BS (%) 2.9 5.9 7.0 ± 4.1
MLT (j) 19.7 23.6 24.5 ± 7.5
BFR (μm3/μm2/j) 0.0267 0.0310 0.0435 ± 0.060
OcN/BA (cell/mm2) 3.44 8.91 3.80 ± 1.70
Oc S/BS (%) 3.1 2.8 1.4 ± 0.5
BV/TV: Bone volume/Tissue volume, OV/BV: Osteoid volume/Bone volume,
MAR: Mineral Apposition Rate, MS/BS: Mineralizing surface/Bone surface,
MLT: Mineralization Lag Time, BFR: Bone Formation Rate, OcN/BA: Osteoclasts
number/Bone area, OcS/BS: Osteoclasts surface/Bone surface.
Note the absence of mineralization defect (normal MLT) in both patients and
normal or increased OC number.was decreased as expected under Bps but OC number,
as assessed by counting TRACP (Tartrate Resistant Acid
Phosphatase) positive cells attached to the bone surface,
was not diminished. Up to three giant OC with more
than 25 nuclei/cell were observed per slide and most of
them were detached from the bone surface [Figure 1].
Osteoid bone and marrow cavity were normal and no
woven bone was observed throughout the biopsy ruling
out hyperparathyroidism or Paget’s disease of bone.
Case 2
The second patient was a 41 year-old woman with renal
insufficiency due to an obstructive nephropathy. She
started hemodialysis at age 24 and underwent a success-
ful renal transplantation at age 38. When she was on
hemodialysis, her BMD score was already reduced that
was confirmed 6 months after transplantation with ele-
vated parathyroid hormone (PTH) and reduced 25-(OH)
D (Table 3, - 36 months). Oral vitamin D (400 i.u twice
daily) was started soon after transplantation and RIS
(35 mg/week) was given one year after when renal functionFigure 1 Giant OC in patient 1 from TRACP staining (400X
magnification). Note the absence of bone resorption,
multinucleated and detached OC from bone surface.
Table 3 Evolution of biological parameters and BMD in patient 2
-36 months -24 months -12 months Bone biopsy +3 months
CTX (250–4500 pmol/L) 13700 ND 4760 3650 6545
Intact PTH (10–65 pg/mL) 127 ND 111 51 59
25-(OH) D (20–90 nmol/L) 22 40 60 62 82
Bone Alkaline
Phosphatase (11.6-30.6 U/L) 21 7 9 10 11
BMD (T-score)
Lumbar -2.6 ND ND -3.3 ND
Femoral neck -3.1 -3.5
CTX: Carboxy-terminal collagen crosslinks; PTH: Parathyroid hormone; BMD: Bone mineral density, ND: not determined.
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normalization of biological parameters (PTH and 25-(OH)
D), an iliac crest bone biopsy was performed while she was
under RIS for 26 months. The bone histomorphometry re-
sults showed a reduced BFR in agreement with Bps treat-
ment [Table 2] while OC number was slightly increased.
Again, multinucleated giant OC were observed, most of
them being detached from the bone surface [Figure 2].
They were not associated with resorption activity and were
absolutely identical to those seen in patient 1. Hyperpara-
thyroidism bone disease and Paget’s disease of bone were
again ruled-out since not abnormalities were reported for
osteoid and marrow cavity.
Discussion
In this report, we described large multinucleated OC on
the edge of bone trabeculae observed on bone biopsies
from two patients under Bps therapy. These patients
were treated with ALN and RIS for respectively 38 and
26 months. These OC had an average length of 92 μm,
mostly detached from bone surface and were notFigure 2 Giant OC in patient 2 from TRACP staining (200X
magnification). Note that these giant OC have the same
characteristics as seen in patient 1.associated with resorption lacunae. No mineralization
defects were seen in both patients (normal osteoid vol-
ume and mineralization lag time) and OC number was
either normal or increased. We observed 2 or 3 of
these giant OC per slide that are not usually accounted
for OcN/BA determination. Furthermore, these large
OC had an apoptotic appearance with a clear nuclear
fragmentation and nuclear peripheral beading when
stained with DAPI (4′-6-Diamidino-2-phenylindole,
data not shown). The BFR was decreased as expected
in both patients as well as the biochemical markers of
bone resorption while under Bps. The osteoid bone,
bone marrow cavity and collagen structure were all
well characterized for appropriate diagnosis to rule out
other bone pathologies such as hyperparathyroidism,
Paget’s disease of bone or neoplasia.
The first paper describing similar OC morphology was
published in the New England Journal of Medicine in
which the authors reported these giant OC in patients
treated with ALN [11]. They reported the results of a
3-year prevention trial of ALN in postmenopausal women
[12]. Fifty-one bone biopsies were performed and they de-
scribed that 27% of OC seen in these biopsies were giant,
multinucleated and detached from bone surface with pyk-
notic nuclei. They found an increased OC number that cor-
related with the cumulative ALN dose and concluded that
long-term ALN treatment was associated with increased
OC number but some of them were undergoing apoptosis.
To better describe the phenotype of these OC, a review
was published in which the authors explain the character-
istics of these giant OC seen from patients under Bps [13].
They reported the presence of these giant OC from iliac
crest bone specimen of a 55 year-old woman treated with
an aminobisphosphonate for 4 years and they discuss the
differential diagnosis including Paget’s disease of bone,
hyperparathyroidism, giant cell tumor and fibrous dys-
plasia. They specify the unique and common charac-
teristics of these OC morphology: often more than 40
nuclear profiles compared to 2–8 nuclear profiles found
in normal OC, detachment from the bone surface and up
to 30% apoptotic.
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as ours in osteoporotic patients treated with nitrogen-
containing Bps during 3 years [14]. They also described a
normal number of OC in these patients that is consistent
with our histomorphometry results. These giant OC were
exactly similar to our description and the one provided
previously.
By our description and those made by others, it seems
therefore plausible that the presence of these non-
resorbing giant OC are directly related to the mecha-
nism of action of the Bps. It has already been shown that
nitrogen-containing Bps interfere with farnesyl pyro-
phosphate synthase in the mevalonate pathway resulting
in a reduced geranylgeranyl diphosphate that is required
for the prenylation of Guanosine triphosphate binding
proteins, hence preventing formation of the ruffled
border of the OC [15,16]. This leads to cytoskeletal mal-
function and ultimately death by apoptosis. The decrease
in OC resorption capability under Bps therapy could
delay OC apoptosis allowing the fusion of OC precur-
sors and produce these large multinucleated and apop-
totic OC as proposed by Weinstein et al [11]. In this
view, it is therefore not surprising that OC number was
reported to be normal or even increased in our patients.
Indeed, this was already noted in animal studies where
RIS and ALN inhibited bone resorption at doses tenfold
lower than what were required to reduce OC number
[16]. In ALN treated rats, multinucleated OC that exhi-
bited poorly organized ruffled borders and detached
from the bone surface have also been reported [17]. It is
important to note that these giant OC are seen not only
in patients treated with nitrogen-containing Bps but also
with amino-Bps as in our case. The identification of
giant multinucleated OC in bone specimens from pa-
tients treated with Bps is of primary importance as it
should not be interpreted as markers of increased bone
resorption. Indeed, the absence of resorption capability,
the detachment from bone surface and the presence of
apoptosis markers characterise these OC and their pres-
ence should not be identified as active OC. Although
our patients were different from the cases described in
the literature since they had secondary cause of osteo-
porosis, our findings are nevertheless identical to pre-
viously reported cases.
Conclusion
Bisphosphonates decrease bone resorption by inducing
OC apoptosis and often allow appearance of multinucle-
ated and giant OC that can be observed on patients
bone tissue. The recent description of these OC gives us
a better understanding on their mechanisms of action
and is essential to recognise for all bone pathologists. In-
deed, these giant OC should not be interpreted as
markers of increased bone remodelling, which could leadto a false diagnosis of Paget’s disease of bone, hyperpara-
thyroidism bone disease or even bone tumour.
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